Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...

Kymera Therapeutics raises $250.8M in public offering to advance its innovative degrader medicines for immunological diseases.

A high-level overview of Trinity Biotech plc (TRIB) stock. View (TRIB) real-time stock price, chart, news, analysis, analyst reviews and more.

Trinity Biotech Plc is listed on the CBOE trading with ticker code TRIB.US. It has a market capitalisation of -, with approximately 0.00 shares in issue. Over the last year, Trinity Biotech Plc ...

Review Trinity Biotech PLC ADR (TRIB:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Welcome to Fierce Biotech's Fundraising Tracker for 2025. June 18—Draig Therapeutics Series: A Amount: $140M Investors: Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures, Schroders ...

Tucson-based biotech firm HTG Molecular Diagnostics has filed for Chapter 11 bankruptcy, with plans to operate as it works out a plan to pay its debts.

Pathway Triangle's King Street Properties confirmed that it has leased manufacturing space in Morrisville. What to know.

The approval enables Trinity to transition upstream production from in-house operations to an outsourced model.

The Trinity in Scripture “And God said, Let us make man in our image, after our likeness: and let them have dominion over the fish of the sea, and over the fowl of the air, ...

Radiopharma start-up Alpha-9 Oncology has closed a sizeable third investment round, heading a list of recent financings that also feature Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth Therapeutics.

J&J's announcement came just hours after GSK confirmed it had agreed a $1 billion deal to buy cancer biotech IDRx and its KIT inhibitor for gastrointestinal stromal tumours (GIST).